"Eleva commences Phase I clinical trial for C3G treatment" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

According to interim data from a phase 2 trial, a single dose of CYB003, Cybin’s deuterated psilocybin analog, resulted in statistically significant improvement in depression symptoms at 3 weeks ...

Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity. Copenhagen, DK and Boston, MA, U.S. November 4, 202 1– Zealand Pharma A/S a ...

The single-center, double-blind, placebo-controlled, and multiple ascending dose (MAD) study will evaluate XW004 at doses of up to 30 mg daily in approximately 56 healthy volunteers. Participants ...

XenoPort Announces Initiation of a Phase 1 Clinical Trial of XP23829, a Novel Fumarate Analog for the Potential Treatment of Relapsing-Remitting Multiple Sclerosis and Psoriasis <0> XenoPort, Inc ...

The Phase 1 trial is a double-blind, randomized, placebo-controlled study investigating the safety, tolerability, and pharmacokinetics of single, subcutaneous dose of the compound, called FT-104 ...

Psychedelics biotech company Cybin Inc.CYB003 Interim findings from the ongoing Phase 1/2a clinical trial showed positive outcomes, including a rapid and short-acting response in participants ...

Background: CKD-602 (Camtobell, Chong Kun Dang Pharm, Seoul, Korea) is a new camptothecin analogue. The objective of this phase II multicenter trial was to investigate the safety and efficacy of ...